Optimizing the dose of dabigatran etexilate

被引：1
作者：
Posner, John [1 ]
机构：
[1] Kings Coll London, Sch Biomed Sci, London WC2R 2LS, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2012年 / 74卷 / 05期
关键词：
THROMBIN INHIBITOR DABIGATRAN; RE-LY TRIAL; ATRIAL-FIBRILLATION; PHARMACODYNAMICS; PHARMACOKINETICS; WARFARIN; TOLERABILITY; THERAPY;
D O I：
10.1111/j.1365-2125.2012.04353.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：741 / 743
页数：3
相关论文
共 13 条
[11]   The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects [J].
Stangier, Joachim ;
Rathgen, Karin ;
Staehle, Hildegard ;
Gansser, Dietmar ;
Roth, Willy .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 64 (03) :292-303
[12]   Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran [J].
Stangier, Joachim ;
Feuring, Martin .
BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (02) :138-143
[13]   Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study [J].
Stangier, Joachim ;
Rathgen, Karin ;
Stahle, Hildegard ;
Mazur, Dago .
CLINICAL PHARMACOKINETICS, 2010, 49 (04) :259-268
12